Head-To-Head Comparison: INVO Fertility (NASDAQ:IVF) & H-CYTE (OTCMKTS:HCYTD)

H-CYTE (OTCMKTS:HCYTD) and INVO Fertility (NASDAQ:IVF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Institutional and Insider Ownership

12.0% of INVO Fertility shares are owned by institutional investors. 5.2% of H-CYTE shares are owned by company insiders. Comparatively, 0.7% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for H-CYTE and INVO Fertility, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
H-CYTE	0	0	0	0	0.00
INVO Fertility	1	0	0	0	1.00

Earnings and Valuation

This table compares H-CYTE and INVO Fertility”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A
INVO Fertility	$6.53 million	0.40	-$9.10 million	($630.30)	0.00

H-CYTE has higher earnings, but lower revenue than INVO Fertility.

Profitability

This table compares H-CYTE and INVO Fertility’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
H-CYTE	-450.40%	N/A	-777.68%
INVO Fertility	-417.02%	N/A	-92.42%

Volatility & Risk

H-CYTE has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, INVO Fertility has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500.

Summary

INVO Fertility beats H-CYTE on 7 of the 9 factors compared between the two stocks.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.